ABAlexandra Barranco

Alexandra Barranco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Barranco has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RANKL inhibition spatially rewires the microenvironment of luminal breast cancer

    by Mario Rodriguez-Del Collado, Andrea Vethencourt, Alexandra Barranco, Jaime Martinez de Villarreal, David Valcárcel-Linares, Eva Maria Trinidad, Eduard Dorca, Gonzalo Soria-Alcaide, Maria Jimenez, Eduardo J. Caleiras, et al.

    Hormone receptor-positive, HER2-negative breast cancers are often poorly infiltrated by immune cells and derive limited benefit from current immunotherapy strategies. Here, using paired tumour samples from the randomised window-of-opportunity D-BIOMARK trial ( NCT03691311 ), we investigated the immunomodulatory effects of denosumab in early luminal breast cancer. Short-term preoperative denosumab reduced tumour-cell proliferative transcriptional programs and immunosuppressive features of the local tumour microenvironment, enhancing innate and adaptive immune activation and altering circulating cytokine profiles. High-resolution spatial transcriptomics revealed coordinated remodelling of tumour, immune, fibroblast and endothelial compartments after treatment. Denosumab reduced immune–tumour spatial separation and enhanced T cell activation, accompanied by a shift from matrix-associated tumour programs towards increased tumour–T cell communication. Copy number-informed tumour-state inference further identified a reduced representation of genomically complex, immune-poor tumour subclones after treatment. Together, these findings identify denosumab as a modulator of tumour–microenvironment crosstalk and support RANKL blockade as a strategy to render immune-poor luminal breast tumours more permissive to immune engagement.

  • Top Cited Papers
    Open Access

    Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis

    by Alejandro Collado-Sole, Nozha Borjini, Jing Zhai, Francisco Ruiz-Pino, Gonzalo Soria-Alcaide, Cintia Folgueira, Celia García-Vilela, Beatriz Romero-De la Rosa, Victor Lopez, Yassine Zouaghi, et al.

    The hypothalamic-pituitary-gonadal axis (HPG) controls pubertal development, sexual maturation, and fertility. We identified a role of hypothalamic microglia in controlling the HPG axis through receptor activator of nuclear factor κB (Rank) signaling. Whole-body and microglia Rank (mouse) depletion led to hypogonadotropic hypogonadism (HH) resulting from an alteration in gonadotropin-releasing hormone (GnRH) neuron function. In addition, we identified rare gene variants of RANK (human) in patients with HH. Transcriptional profiling upon Rank loss revealed defective microglia activation and morphological alterations in the median eminence, decreasing the contacts and engulfment of GnRH terminal projections and impairing GnRH neuronal responses to kisspeptin. Overall, our data uncover the microglia as regulator of GnRH neuronal function through Rank signaling, with potential implications for reproductive maturation and fertility.